Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses the date of the RESORCE Trial and how it changed the role of regorafenib in the treatment of unresectable HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
RESORCE Trial: Role of Regorafenib in Unresectable HCC Treatment
